Reports Q2 revenue $23.52M, consensus $23.08M. “We are pleased with the continued momentum in our business through the second quarter of 2025, as we made significant progress across a number of key initiatives to position NeuroPace (NPCE) for sustained long-term growth,” said Joel Becker, CEO. “We are advancing our strategy, driving increased access to and adoption of RNS therapy and supporting operating leverage as we scale.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NPCE Upcoming Earnings Report: What to Expect?
- NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- NeuroPace Appoints New CFO Amid Strategic Shift
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed